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7RESEARCH Open AccessDefinitive intensity modulated radiotherapy in
locally advanced hypopharygeal and laryngeal
squamous cell carcinoma: mature treatment
results and patterns of locoregional failure
Andreas Geretschläger1, Beat Bojaxhiu1, Alan Dal Pra1*, Dominic Leiser1, Michael Schmücking1, Andreas Arnold2,
Pirus Ghadjar1 and Daniel M Aebersold1Abstract
Purpose: To assess clinical outcomes and patterns of loco-regional failure (LRF) in relation to clinical target volumes
(CTV) in patients with locally advanced hypopharyngeal and laryngeal squamous cell carcinoma (HL-SCC) treated with
definitive intensity modulated radiotherapy (IMRT) and concurrent systemic therapy.
Methods: Data from HL-SCC patients treated from 2007 to 2010 were retrospectively evaluated. Primary endpoint was
loco-regional control (LRC). Secondary endpoints included local (LC) and regional (RC) controls, distant metastasis free
survival (DMFS), laryngectomy free survival (LFS), overall survival (OS), and acute and late toxicities. Time-to-event
endpoints were estimated using Kaplan-Meier method, and univariate and multivariate analyses were performed
using Cox proportional hazards models. Recurrent gross tumor volume (RTV) on post-treatment diagnostic imaging
was analyzed in relation to corresponding CTV (in-volume, > 95% of RTV inside CTV; marginal, 20–95% inside CTV;
out-volume, < 20% inside CTV).
Results: Fifty patients (stage III: 14, IVa: 33, IVb: 3) completed treatment and were included in the analysis (median
follow-up of 4.2 years). Three-year LRC, DMFS and overall survival (OS) were 77%, 96% and 63%, respectively. Grade 2
and 3 acute toxicity were 38% and 62%, respectively; grade 2 and 3 late toxicity were 23% and 15%, respectively. We
identified 10 patients with LRF (8 local, 1 regional, 1 local + regional). Six out of 10 RTVs were fully included in both
elective and high-dose CTVs, and 4 RTVs were marginal to the high-dose CTVs.
Conclusion: The treatment of locally advanced HL-SCC with definitive IMRT and concurrent systemic therapy provides
good LRC rates with acceptable toxicity profile. Nevertheless, the analysis of LRFs in relation to CTVs showed in-volume
relapses to be the major mode of recurrence indicating that novel strategies to overcome radioresistance are required.
Keywords: Hypoharyngeal cancer, Laryngeal cancer, IMRT, Patterns of failure, RadiotherapyBackground
Radical surgical treatment of locally advanced squamous
cell carcinoma of the hypopharynx or larynx (HL-SCC)
often requires total laryngectomy (TL). Landmark clin-
ical trials for laryngeal [1] and hypopharyngeal cancers
[2] have shown that organ preserving treatments such as
induction chemotherapy followed by radiotherapy (RT)* Correspondence: alan.dalpra@insel.ch
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unless otherwise stated.are non-inferior to surgical treatment followed by RT.
Subsequently, concurrent chemoradiation further improved
locoregional control (LRC) in comparison to sequential
induction chemotherapy and RT in the RTOG 91-11 trial
[3,4] and is since regarded as standard treatment for locally
advanced HL-SCC.
In the last decade intensity-modulated radiotherapy
(IMRT) has replaced 3D conformal RT for definitive
treatment of locally advanced head-and-neck cancers
due to the highly conformal dose distribution with steep
gradients towards the surrounding healthy tissues therebyentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prospective randomized trial, parotid-sparing IMRT sig-
nificantly reduced xerostomia compared to 3D conformal
RT [7]. Of note, a tight conformal dose distribution might
instead increase the likelihood of geographical miss
and locoregional failure (LRF) [8]. Patients with locally
advanced HL-SCC have a high probability of both clinically
evident and occult lymph node metastasis and subclinical
mucosal tumor spread. IMRT treatment should be accom-
panied by a rigorous quality assurance program in order to
provide early identification and analysis of locoregional
treatment failures. Having introduced IMRT in our institu-
tional clinical practice in 2002, we reevaluated and adapted
our guidelines for target volume definition for HL-SCC in
2007 drawing upon our own experience as well as early
publications on IMRT in head-and-neck cancers [9-11].
With the aim of further improving treatment results
through continuous analysis of our LRF patterns we have
retrospectively analyzed mature clinical outcomes and
toxicity patterns of a cohort of patients treated from 2007
onwards according to these standards.
Methods
Patient selection
Patients with locally advanced HL-SCC [American Joint
Committee on Cancer (AJCC) stage III or IV] treated
with curative IMRT treatment between January 2007 and
December 2010 at the Department of Radiation Oncology,
Inselspital, Bern University Hospital were retrospectively
assessed. Ineligibility criteria included patients older than
85 years, initial Karnofsky Performance Status (KPS) less
than 60%, history of another malignancy within 5 years of
diagnosis, prior RT to the head and neck, histology other
than squamous cell carcinoma and distant metastatic dis-
ease. Patients who underwent radical surgical procedures
to the primary tumor were excluded, but functional tumor
debulking and/or primary neck dissections (ND) were
allowed. Patients who did not reach the prescribed RT
dose or did not finish treatment within 60 days since
delivery of the first RT fraction were excluded. Living
patients with documented follow-up of less than one year
were also excluded from analysis. This study was approved
by the local research ethics committee and the Swiss
Federal Office of Public Health (FOPH) (035.0001-90).
Treatment
All cases were presented at the weekly institutional interdis-
ciplinary head-and-neck tumour board. After completion
of staging examinations and final TNM staging (AJCC),
selection of treatment modalities and treatment sequencing
were defined. Pre-treatment staging involved laryngoscopy,
measurement of the tumour, and high-resolution computed
tomographic (CT) scanning of the primary tumour and the
neck with or without magnetic resonance imaging (MRI).Prior to 2008, imaging for systemic staging was per-
formed as clinically indicated; and from 2008 onwards
positron emission tomography with 2-deoxy-2-[fluorine-
18]fluoro-D-glucose integrated with computed tomography
(18F-FDG PET/CT) was regularly used in the staging of
locally advanced cases to rule out distant metastasis,
synchronous malignancies, and gain additional information
on lymph node metastasis, especially on retropharyngeal
(RP) node status. All patients were referred to dental evalu-
ation before start of RT. Prophylactic feeding tube insertion
via gastrostomy was recommended to most of the patients.
Radiotherapy
For treatment planning a dedicated high-resolution CT
scan with 3 mm slices and intravenous contrast was used.
Patients were immobilized in the supine position using a
thermoplastic mask covering head and shoulders. No bite
bock was used to facilitate dorsal hyperflexion of the
cervical spine. Patients were additionally instructed to
keep the tongue extended during treatment if possible.
All visible surgical scars were marked with flexible wires if
a neck dissection had been performed. All target volumes
and organs at risk were contoured on the planning CT
scan. Image fusion of diagnostic MRI and/or PET-CT with
the planning CT was performed if cervical spine flexion
was similar resulting in an acceptable matching distortion.
Gross tumor volume (GTV) consisted of the primary
tumor (or residual tumor after debulking in two patients)
and pathologic lymph nodes as clinically diagnosed and
visualized on all available imaging. High-risk CTV72 was
derived from the GTV with an additional isotropic margin
of 5 – 12 mm. Only in patients with prior ND, a high-risk
CTV66 was defined as the levels of the original gross
involved nodes harbouring extracapsular extension (ECE),
as reconstructed from the preoperative imaging, with an
additional isotropic margin of 5 – 15 mm. In nodal stages
pN2a and pN3 we generally assumed presence of ECE even
if not explicitly stated in the histopathologic report. In cases
of reported intraoperative lymph node spillage the complete
area of neck dissection was included in the CTV66.
In patients with ND and nodal stages pN1, pN2b,
pN2c without ECE, the standard risk CTV54 included all
dissected neck levels and the surgically manipulated area
as proposed by Gregoire et al. [12] and all non-dissected
elective lymph node levels bilaterally. In patients without
ND, CTV54 included all elective lymph node levels
bilaterally. The definition of elective nodal target volumes
in respect to size and location of the primary tumor
followed the recommendations proposed by Eisbruch
et al. [13] and consensus guidelines [14] with minor
adjustments. In clinical or pathological nodal stages N1,
N2a and N2b, we did not include the cranial half of
contralateral level II to spare contralateral parotid gland
neither caudal half of contralateral level IV. When present,
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In cases of ipsilateral level II involvement, CTV54
extended cranially to the base of skull on the ipsilateral
side including the retro-styloid space [11]. If ipsilateral
level II was not involved in nodal stage N1, N2a, N2b, we
also considered sparing the cranial half of ipsilateral level
II. In the absence of metastatic RP nodes after diagnostic
imaging with MRI and PET-CT, elective coverage of RP
were limited to 3-4 cm cranially to the GTV.
All prescribed CTV margins were manually adapted
to account for anatomical barriers such as thyroid and
cricoid cartilages, hyoid, mandibular or vertebral bones,
skin and air. The resulting CTVs were finally expanded
to planning target volumes (PTVs) by adding a symmetric
3 mm margin for setup error compensation. In a final
adjustment PTVs were set back from the skin surface
3 mm to allow for dose build-up except where the skin
was deemed to be at risk of microscopic disease. Instead
of using a skin flap in these cases we tried to optimize
dose build-up by putting more weight on tangential beam
directions accepting minor under-dosage. Prescribed doses
to PTV72, PTV66 and PTV54 were 72 Gy, 66 Gy and 54
Gy, respectively. All PTVs were treated sequentially in a
“shrinking-volume” technique with a fractionation of 5
times per week, 2Gy per fraction, resulting in two or three
treatment plans per patient. All PTVs were comprehen-
sively covered in one IMRT plan without field junctions.
The total dose was prescribed to the median dose (D50%)
of the PTV in accordance with the ICRU report 83.
Pre-treatment setup imaging was performed daily. All treat-
ment plans were contoured and calculated using Eclipse
treatment planning system (Varian Medical Systems, Palo
Alto, CA).
Concomitant systemic therapy
The standard concomitant therapy consisted of cisplatin
100mg/m2 day 1 in three-week intervals for all patients. In
few cases of induction chemotherapy, cisplatin, docetaxel
and 5-fluorouracil were used. Patients not deemed medic-
ally fit for cisplatin chemotherapy because of pre-existing
co-morbidities were evaluated for weekly treatment with
monoclonal antibody cetuximab [15] or carboplatin three
weekly. Patients who did not tolerate the toxicity of
cisplatin treatment were switched to either carboplatin
as described or to low dose carboplatin weekly or to
cetuximab at the discretion of the medical oncologist.
Assessments and evaluations
After treatment all patients underwent follow-up visits
on a regular basis. These visits were scheduled every 3
months for the first 2 years, twice a year until the 5th
year and yearly thereafter. For this study the follow-up
information closeout date was December 2011 to guar-
antee a minimum follow-up of one year. A post-therapybaseline CT or MRI was performed eight to twelve
weeks after the end of treatment. Time-to-event end-
points were calculated from end of IMRT until the date
of event. Patients not experiencing an event were cen-
sored at the date of the last follow-up visit.
Toxicities were graded according to the National Cancer
Institute (NCI) Common Terminology Criteria for adverse
events (CTCAE) version 3.0. The symptoms of pain,
dermatitis, mucositis, dysphagia, xerostomia and osteo-
necrosis were assessed. Acute and late toxicity were
defined as post-treatment-related complications during
and/or within 3 months after chemo-RT, and after 3
months, respectively. Baseline pre-treatment assessments
using the same criteria were also performed.
Analysis of locoregional failures
The earliest diagnostic imaging showing any LRF was
matched to the planning CT and the treatment plan. All
recurrent and/or persistent local or regional macroscopic
tumor volumes (RTV) were then delineated on the plan-
ning CT and a quantitative comparison of the volume con-
gruency was used to categorize the LRF as “in-volume”,
if >95% of the RTV was included in the corresponding
CTV54, CTV66 or CTV72; “marginal”, if 20–95%, and
“out-volume”, if <20% of the RTV was included within
the corresponding CTV, as previously described [16]. The
relation of the RTVs to all CTVs was assessed sequentially.
We decided to quantitatively compare RTVs to CTVs as
opposed to treatment plan isodose lines [17] to better
evaluate the accuracy of our target volume delineation
and dose prescription.
Statistical considerations
The primary endpoint was locoregional control (LRC).
Secondary endpoints included local (LC) and regional
(RC) controls, distant metastasis-free survival (DMFS),
laryngectomy-free survival (LFS), overall survival (OS), acute
and late toxicities. Late toxicity at last follow-up visit was
also assessed to determine whether the late toxicity persisted
or was transient. Time-to-event endpoints were estimated
using the Kaplan-Meier method. Univariate and multivariate
analyses were performed using Cox proportional hazards
models. Known prognostic variables were analyzed in the
multivariate analysis and a stepwise backward selection
method (criterion for removal: p ≥0.05) was applied. Vari-
ables were summarized using absolute and relative frequen-
cies. P-values were two-sided, not adjusted for multiple
testing, and considered significant if < 0.05. The data were
analyzed in SPSS (SPSS Inc., Chicago, IL, version 21.0).
Results
Patient and treatment characteristics
Of the 54 patients that met initial inclusion criteria and
had started treatment, 3 did not finish treatment because
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aspiration, feeding tube insertion complication) and 1
had a total treatment time > 60 days, being excluded
from final analysis. Finally, 50 patients were analyzed, 26
with hypopharyngeal cancers and 24 laryngeal cancers.
Pre-treatment diagnostic imaging of the head and neck
was performed either by CT (n = 20), MRI (n = 21) or
both (n = 9). Whole body staging consisted of a chest
CT scan (n = 6), a PET-CT scan (n = 25) or both (n = 11).
The remaining 8 patients had a chest radiograph.
Twenty-two patients (44%) underwent upfront ND, 13
of which were unilateral and 9 were bilateral. ECE was
diagnosed histopathologically in 13 cases (10 ipsilateral
only, 1 contralateral only, 2 bilateral). Two patients had
a transoral debulking laser surgery to the primary tumor
to improve breathing. Forty-three patients (86%) under-
went either both neoadjuvant and concomitant (n = 7) or
concomitant only (n = 36) systemic therapy. Concomitant
therapy consisted of cisplatin (100mg/m2 three-weekly
interval) in 25 cases (mean number of cycles 2.7; range
1-3), carboplatin (AUC5 three weekly interval or AUC2
weekly interval) in 7 cases or monoclonal antibody
cetuximab in 9 cases (mean number of applications 6,
range 1-8). Two patients started chemoradiation with
cisplatin and continued with carboplatin because of
toxicity. Seven patients were not deemed fit for any
systemic therapy. Median RT total dose was 72 Gy (range,
66 - 74). One patient received 74 Gy to compensate for
treatment interruption. Median treatment time was 51.7
days (range, 47 - 61), median follow-up for the surviving
patients was 4.2 years (range, 1.0 – 6.6) and median
follow-up for all patients was 3.2 years (range, 0.1 – 6.6).
Further patient and treatment characteristics are summa-
rized in Table 1.
Disease control, salvage surgery and patterns of failure
At the time of analysis 10 patients had developed LRF with
the following characteristics: 8 unifocal local recurrences, 1
unifocal regional recurrence, 1 patient with combined local,
multifocal regional and distant recurrence. One patient
presumably died of tumor progression before restaging
therefore this patient was not included in the detailed ana-
lysis of patterns of failure. The isolated regional recurrence
occurred ispilaterally in a patient with ND prior to IMRT,
and there was no contralateral regional failure. Median
time to LRF was 0.8 years (range, 0.4 – 2.3). Kaplan-Meier
estimates at 2 and 3 years for LRC were 80% and 77%,
respectively (Figure 1a). Kaplan-Meier estimates at 2 and
3 years for LC and RC were 80% and 78% and 96% and
96%, respectively (Figure 1b-c). Neither in univariate nor
in multivariate testing could a significant prognostic factor
for LRC be identified (Table 2).
Diagnosis of LRF could be established within the first
(n = 7), second (n = 2) or third year (n = 1) after completionof treatment. Salvage surgery was offered to 7 patients but
performed in 6 patients (1 patient refused and underwent
palliative chemotherapy). Only 1 patient profited at long-
term being alive without evidence of disease (follow up time
of 48 months post-surgery), and the remaining 5 patients
suffered from incomplete resection, repeated recurrences
and protracted postsurgical complications and finally died
[median survival post salvage surgery of 7 months (range
3-24 months)]. Two patients underwent a second course
of RT following salvage surgery.
LRF pattern analysis could be performed in 10 of the
11 patients. The RTVs were completely covered by the
standard risk CTV54 in 9 of the 10 patients (90%) and 1
RTV was marginal to CTV54. RTVs were completely
covered by the high-risk CTV66 and CTV72 in 6 out of
10 patients (60%) but 4 RTVs (40%) were marginal to
the respective high-risk CTV. There was no out-volume
failure (Table 3).
Distant metastasis and overall survival
At the time of analysis, 2 patients developed distant
metastasis, located in the lung (n = 1) and soft tissue
and lung (n = 1). One patient with metastasis was sim-
ultaneously diagnosed with LRF. Median time to distant
metastasis was 0.6 years (range, 0.5 – 0.8). Kaplan-
Meier estimates at 2 and 3 years for DMFS were 96%
and 96%, respectively (Figure 2a).
Twenty-one patients (42%) died during follow-up: 11
(22%) due to cancer progression including 10 of 11
patients with LRF and 1 with distant metastasis, 3 (6%)
due to second malignancies, 5 (10%) due to preexisting
medical co-morbidities (GI-bleeding, myocardial infarc-
tion, stroke, chronic obstructive airway disease, pulmonary
embolism) and 2 (4%) due to unknown reasons. Kaplan-
Meier estimates at 2 and 3 years for OS were 69% and
63%, respectively (Figure 2b). Neither in univariate nor in
multivariate testing could a significant prognostic factor
for OS be identified (Table 2).
Pre-treatment morbidity, acute and late toxicity
Toxicity data including pre-treatment morbidity is pre-
sented in Table 4. Prior to RT start, 10 patients (20%)
had grade 2 pain, 4 (8%) had grade 2 dysphagia and 3
(6%) had grade 3 dysphagia.
The highest-grade acute toxicities were grade 2 in 19
patients (38%) and grade 3 in 31 patients (62%). There
were no grade 4 or 5 toxicities, and no treatment was
interrupted due to toxicity. The highest-grade late toxic-
ities were grade 2 in 11 patients (23%) and grade 3 in 7
patients (15%). At the last follow-up 6 patients (13%)
still presented grade 2; and 2 patients (4%) presented
grade 3 toxicity. Of note, highest-grade toxicity rates at
the last follow up were inferior to the pre-treatment
morbidity rates (Table 4).
Table 1 Patient and treatment characteristics (n = 50)
Characteristics n (%)
Age (years)β
≤60 19 (38))
≥60 to≤ 70 20 (40)
>70 to≤ 85 11 (22)
Gender
Female 5 (10)
Male 45 (90)
Karnofsky PS
>70 45 (90)
≤70 5 (10)
Site
Hypopharynx: Post cricoid area 10 (20)
Hypopharynx: Piriform sinus 14 (28)
Hypopharynx: Posterior pharyngeal wall 2 (4)
Larynx: Supraglottis 14 (28)
Larynx: Glottis 10 (20)
Tumor classification
cT1 2 (4)
cT2 5 (10)
cT3 27 (54)
cT4 16 (32)
Nodal classification
cN0 11 (22)
cN1 8 (16)
cN2 11 (38)
cN3 2 (4)
pN1 2 (4)
pN2 15 (30)
pN3 1 (2)
Grading
Moderate (G2) 32 (64)
Poor (G3) 18 (36)
Neck dissectionπ*
None 28 (56)
Ipsilateral 13 (26)
Bilateral 9 (18)
Tracheotomy
Before radiotherapy 7 (14)
During radiotherapy 9 (18)
After radiotherapy 3
Gastrostomy tube
None 17 (34)
Used 33 (66)
Abbreviations: PS performance status, βmedian 63 years (range, 45-84 years);
πMedian of 56 nodes removed (range, 18 - 106 nodes); *Median time from neck
dissection to radiotherapy was 42 days (range, 23 – 59 days); RT = Radiotherapy.
Figure 1 Kaplan–Meier curves for locoregional control (a), local
control (b) and regional control (c) for patients with locally
advanced hypopharyngeal and laryngeal cancers treated with
definitive IMRT.
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Feeding tube insertion via percutaneous endoscopic gas-
trostomy (PEG) was generally recommended, though 24
(48%) patients refused it. PEG was finally performed prior
to start of IMRT in 26 (52%) patients, during IMRT in 5
(10%) patients and in 2 (4%) patients after LRF (9 and 10
months after completion of treatment, respectively). A
Table 2 Treatment outcome analysis
Factor Associated level Cox regression analysis: hazard ratio (95% CI) (p-value)
LRC OS
Univariate analysis
Age (years) >60 0.86 (0.26, 2.817) (0.80) 1.96 (0.76, 5.07) (0.17)
Sex Male 1.14 (0.15, 8.91) (0.90) 0.97 (0.23, 4.16) (0.96)
Localisation Larynx 1.29 (0.39, 4.24) (0.67) 1.04 (0.44, 2.45) (0.94)
T-classification cT3-4 1.29 (0.16, 10.06) (0.81) 0.53 (0.18, 1.58) (0.26)
N-classification c/pN2b-3 1.13 (0.33, 3.87) (0.84) 0.78 (0.33, 1.83) (0.57)
AJCC stage IV 0.90 (0.24, 3.40) (0.88) 0.91 (0.35, 2.35) (0.91)
Grading G3 0.88 (0.26, 3.01) (0.84) 0.75 (0.30, 1.85) (0.53)
Neck Dissection yes 1.48 (0.45, 4.86) (0.52) 0.19 (0.51, 2.81) (0.69)
Duration RT >55 days 1.08 (0.23, 5.01) (0.92) 0.70 (0.21, 2.40) (0.57)
Multivariate analysis
Age (years) >60 0.93 (0.27, 3.39) (0.93) 2.37 (0.83, 6.73) (0.11)
Sex Male 1.28 (0.13, 12.43) (0.83) 0.79 (0.14, 4.42) (0.79)
Localisation Larynx 1.31 (0.33, 5.12) (0.70) 1.32 (0.46, 3.75) (0.60)
T-classification cT3-4 1.51 (0.14, 10.79) (0.73) 0.50 (0.12, 2.05) (0.26)
N-classification c/pN2b-3 1.26 (0.13, 12.32) (0.85) 0.55 (0.15, 2.02) (0.57)
AJCC stage IV 0.51 (0.05, 5.38) (0.57) 0.92 (0.45, 8.15) (0.38)
Grading G3 1.13 (0.28, 4.57) (0.87) 0.99 (0.36, 2.74) (0.98)
Neck Dissection yes 1.83 (0.34, 9.89) (0.49) 1.54 (0.52, 4.55) (0.43)
Duration RT >55 days 1.11 (0.22, 5.50) (0.90) 0.65 (0.17, 2.43) (0.52)
Abbreviations: LRC Locoregional control, OS Overall survival, CI confidence interval.
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tube support. Median time to feeding tube removal was 8
months (range, 1-25). All 29 living patients were without
feeding tube at last follow-up visit and had regular oral
nutritional intake.Table 3 Patterns of recurrence according to CTV coverage
Patient Primary
tumor
Local vs.
regional failure
Full coverage
by CTV54
Marginal
coverage
by CTV54
F
b
1 larynx local Yes No Y
2 hypopharynx local Yes No N
3 hypopharynx local Yes No Y
4 larynx local Yes No Y
5 larynx local Yes No N
6 hypopharynx regional Yes No N
7 larynx local Yes No N
8 larynx local and regional Yes No N
9 hypopharynx local Yes No N
10 hypopharynx local Yes No Y
Abbreviations: CTV clinical target volume, CTV54 clinical target volume covered by 5
volume covered by 72Gy, NA non-applicable.Tracheostomy tube insertion and salvage laryngectomy
A total of 9 patients needed a tracheostoma to be able to
receive treatment; tracheostomy was performed prior to
IMRT start in 8 patients and during IMRT in 1 patient.
Another 3 patients had a tracheostomy because of LRFull coverage
y CTV66
Marginal
coverage
by CTV66
Full coverage
by CTV72
Marginal
coverage
by CTV72
Most probable
explanation
for relapse
es No Yes No radioresistance
A NA No Yes underdosage
es No Yes No radioresistance
es No No Yes underdosage
A NA Yes No radioresistance
o Yes No Yes underdosage
A NA Yes No radioresistance
A NA Yes No radioresistance
o Yes No Yes underdosage
es No Yes No radioresistance
4Gy, CTV66 clinical target volume covered by 66Gy, CTV72 clinical target
Figure 2 Kaplan–Meier curves for distant metastasis free survival
(a) and overall survival (b) for patients with locally advanced
hypopharyngeal and laryngeal cancers treated with definitive
IMRT.
Table 4 Pre-treatment morbidity and acute and late
toxicity
Pre-Tx Acute† Late‡ Last late§
Toxicity Grade n (%) n (%) n (%)** n (%)**
Pain 0 24 (48) - 36 (77) 42 (90)
1 16 (32) 3 (6) 5 (11) 2 (4)
2 10 (20) 34 (68) 4 (8) 1 (2)
3 - 13 (26) 2 (4) 2 (4)
Dermatitis 0 50 (100) 1 (2) 46 (98) 47 (100)
1 - 5 (10) 1 (2) -
2 - 31 (62) - -
3 - 13 (26) - -
Mucositis 0 50 (100) 3 (6) 46 (98) 47 (100)
1 - 8 (16) 1 (2) -
2 - 31 (74) - -
3 - 8 (16) - -
Dysphagia 0 20 (40) 1 (2) 28 (60) 37 (78)
1 23 (46) 5 (10) 7 (15) 5 (11)
2 4 (8) 27 (54) 8 (17) 5 (11)
3 3 (6) 17 (34) 4 (8) -
Xerostomia 0 50 (100) 37 (74) 23 (49) 40 (85)
1 - 9 (18) 21 (45) 6 (13)
2 - 4 (8) 3 (6) 1 (2)
3 - - - -
Osteonecrosis 0 50 (100) 49 (98) 45 (96) 46 (98)
1 - - - -
2 - - - -
3 - 1 (2) 2 (4) 1 (2)
Highest* 0 13 (26) - 15 (32) 30 (64)
1 20 (40) - 14 (30) 9 (19)
2 14 (28) 19 (38) 11 (23) 6 (13)
3 3 (6) 31 (62) 7 (15) 2 (4)
Abbreviations: Pre-Tx pre-treatment morbidity, *The highest morbidity/toxicity
in a patient was counted as a single event; †During therapy and until 3 months
after completion; ‡Maximal late toxicity > 3 months after completion of therapy;
§Incidence of late toxicity at last follow-up visit. **3 patients died within the acute
toxicity period.
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were performed, all in the setting of surgical salvage after
LRF. No laryngectomy was performed because of chon-
dronecrosis or dysfunction. At the last follow-up, 28 of 29
living patients were free of tracheostomy tubes with a
functional larynx. The 2 and 3 year LFS estimates were
86% and 86%, respectively (Figure 3).
Discussion
The majority of publications reporting IMRT outcomes in
head and neck cancers include an inhomogenous patient
selection concerning primary site, stage and definitive or
postoperative use of IMRT [11,17-22]. In the past years a
growing number of studies have reported definitive IMRT
outcomes for HL-SCC as summarized in Table 5.
This work reports our single institution experience
that includes treatment results of a well-defined cohort of
50 locally advanced HL-SCC patients treated with IMRT
with an analysis of RTVs in relation to corresponding
CTVs. Our RT fractionation (single and total doses), PTV
dose prescription and concurrent chemotherapy regimenare well established in literature [3]. Although two patients
underwent debulking procedures of the primary lesion we
would still call it “definitive” or primary IMRT, as these
two surgeries were not radical resulting in gross residual
disease, thus the same principles for CTV definition to the
primary were applied. On the other hand, anatomical
changes due to upfront ND performed in 23 patients
required adaptations in the CTV delineation of the neck
in accordance to the specific clinical settings. Although
this could have been a source of heterogeneous outcomes,
CTV contouring followed standardized guidelines and
important deviations were not seen.
Figure 3 Kaplan–Meier curves for laryngectomy free survival of
patients with locally advanced hypopharyngeal and laryngeal
squamous cell carcinoma treated with definitive IMRT.
Table 5 Selected series of hypopharygeal and laryngeal cance
Study/Year N Site of
primary
AJCC Stage Median FU in
months (range
Miah 2012 [23]
HC + LC
II: 2
Grp1: 29 III: 28 51 (12-77)
Grp2: 31 IV: 30 36 (04-63)
Nguyen 2012 [24]
27 LC
III: 17 20 (6-57)
IV: 10
Liu 2010 [22]
27 HC
II: 5 36 (2-82)
III: 4
IV: 18
Huang 2010 [25]
33 HC
II: 2 25.8 (14.2-72.3)
III: 5
IV: 26
Studer 2010 [26]
123 HC+LC
II: 16
26 (3-83)III: 23
IV: 77
Daly 2011 [27]
31 HC+LC
II: n.r.
30 (13-98)III: n.r.
IV: n.r.
Mok 2014 [28]
181 HC n.r.
IMRT: 50.4
3D-RT: 106.8
Lee 2007 [29]
31 HC+LC
III: 9
24 (17-58)
IV: 21
Current study
50 HC+LC
III: 14
39 (1-79)
IV: 36
Abbreviations: N number of patients, AJCC American Joint Commission on Cancer, F
Volume, LRC loco-regional control, OS overall survival, Grp1 Group treated with mod
HC Hypopharyngeal cancer, LC Laryngeal Cancer, n.r. not reported.
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able with previously published outcome data following
definitive IMRT treatment for locally advanced HL-SCC
(Table 5). Of note, our experience confirms the import-
ance of the primary treatment for effective LRC due to
the very limited results achieved with salvage surgery.
Although there are few data on LFS published, our LFS
estimates were in the range of recent publications [28].
Detailed analysis of LRF revealed 4 marginal failures (3
local and 1 regional), where the RTVs were not fully
covered by the high-dose CTV66 or CTV72 (Table 3).
The isolated regional failure occurred in a patient with
bilateral ND, tracheostomy and bilateral ECE and was
located at the medial caudal edge of the right neck with
infiltration of the thyroid gland. Compared to the treat-
ment plan, about half of the RTV was outside the identi-
fiable surgically manipulated area of the ND and thus
not covered by the CTV66. Intraoperative seeding of
tumor cells might explain the unusual location; howeverr patients treated with definitive IMRT
)
PTV-HD dose
prescription
Margin GTV
to PTV-HD
LRC OS
23 mm or entire
organ + 3 mm
Grp1: 63Gy/28f Grp1: 67%, 2y 72%, 2y
Grp2: 67Gy/28f Grp2: 82%, 2y 74%, 2y
70Gy/35f
5-10 mm n.r.
80%, 2y
62%, 3y
72.6Gy/35f
5 mm 63%, 5y 35%, 5y76.8Gy/37f
70Gy/35f
4 mm n.r. 44%, 5y
66Gy/30f
10-15 mm 77%, 2y 83%, 2y69.6/33f
70Gy/35f
66Gy/30f 8-13 mm 80%, 3y 46%, 3y
60Gy/25f
5-10 mm
IMRT: 75%, 3y IMRT: 50%, 3y
62Gy/40f
64Gy/40f 3D-RT: 58%, 3y 3D-RT: 52%, 3y
70Gy/35f
70Gy/33f 5-10 mm
LRPFS
63%, 2y
84%, 2y
70Gy/35f 8-15 mm
80%, 2y 69%, 2y
77%, 3y 63%, 3y
U Follow-Up, PTV-HD Planning Target Volume High-Dose, GTV Gross Tumor
erate acceleration, Grp2 Group treated with dose escalation,
Geretschläger et al. Radiation Oncology  (2015) 10:20 Page 9 of 10we did not see how this could have been accounted for
at the time of target volume definition. The remaining
three marginal failures were isolated local failures; all
three had advanced T3/T4 primaries. Perhaps an under-
estimation of the GTV extent might have contributed to
the marginal local failures as two patients were initially
staged with CT and PET-CT, but did not have MRI (one
patient had claustrophobia). The GTV to PTV margin
was at the lower end of our range with the intention to
spare dose to pharyngeal constrictor muscles. Based on
the described experience, we have meanwhile introduced
additional locoregional MRI imaging for all locally
advanced cases and discussed expansion of the mini-
mum GTV to PTV high-risk margin in selected cases
especially when the primary tumor is ill-defined with dif-
ficult GTV delineation. Our target volume definition for
the standard risk CTV54 seemed to be adequate with
only one of 10 RTV marginal to CTV54 and the rest
completely in-volume. Overall, neck control was high
with only 2 regional failures and a 2-year regional con-
trol of 96%. A higher number of regional failures outside
high dose volume could be explained by limitations in
clinical lymph node staging. Our low rates of regional
failures could be partially the result of the therapeutic
effect of upfront ND providing improved pathologic
staging in selected cases prior to definitive IMRT. Up-
front ND offers encouraging LRC and survival rates in
retrospective cohorts [30] however its definite role still
warrants validation in randomized trials.
There are different methods for assessing and classify-
ing RTVs in relation to the initial treatment plan, being
challenging to thoroughly compare patterns of failure
between publications. Dawson et al. [17] compared the
RTV to the respective 95% prescription isodose line of
the treatment plan, and Chao et al. [16] compared the
RTV to the respective CTV. Both defined marginal
recurrence if more than 5% of the RTV is outside of the
respective 95% isodose line or CTV, respectively. In
contrast, other authors [21] defined marginal recurrence
if more than 50% of the RTV was outside the respective
95% isodose line. If we had used this definition, we
would have reported only one RTV marginal to the
high-risk CTV with 9 of 10 (90%) RTV fully covered.
When classifying RTV as “in-volume”, “marginal” or “out-
volume”, additional important data should be provided as
which CTV (high- or standard-risk) or which dose pre-
scription was used as reference. In some publications
regional recurrences fully included in the elective nodal
target volume and having been irradiated with the elective
dose are reported as “in-volume” recurrence only. We
think that these recurrences are indeed “in-volume” to the
standard risk CTV but “out-field” to the high-risk CTV
thus should be classified as such, indicating that the dose
prescription to the RTV region was not sufficient.Our cohort showed that although there were marginal
recurrences potentially explained by an underdosage of
the tumor, radioresistant clones continue to be a major
barrier in the treatment of head and neck tumors. Altered
RT fractionation (e.g. accelerated regimens) can shorten
the overall treatment duration, thereby attempting to
minimize tumor repopulation as a cause of treatment
failure. Nevertheless the available data suggest that
accelerated RT regimens do not improve OS when given
with concurrent chemotherapy and/or cetuximab [31,32].
Numerous molecularly targeted agents directing specific
cell signaling pathways involved with radioresistance (e.g.
VEGF, DNA repair, apoptosis, hypoxia, and proliferation)
have been tested in preclinical and clinical studies [33].
In addition, novel strategies to enhance patients’ strati-
fication using molecular and genetic signatures along
with HPV status as biomarkers of treatment response
need to be further explored and timely incorporated
into the decision-making process.
Conclusion
Our study confirms that definitive, conventionally frac-
tionated IMRT in locally advanced HL-SCC results in
good LRC rates with acceptable toxicity profile. Our pat-
tern of failure analyses shows predominantly local failures
with high rates of regional and distant control. Although
the recurrences marginal to the high-risk CTV imply that
optimization in RT volumes could improve outcomes,
in-volume relapses are the major type of recurrence,
which underlines the need for better strategies to overcome
tumor radioresistance.
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